|Bid||43.43 x 1800|
|Ask||43.44 x 800|
|Day's Range||42.96 - 43.81|
|52 Week Range||35.10 - 48.82|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.73|
Hologic, Inc. (NASDAQ:HOLX), a large-cap worth US$13b, comes to mind for investors seeking a strong and reliable stock investment. One reason being its ‘too big to fail’ aura which gives it the appearance of a strong and stable inv...
Health care stocks have fallen out of favor due to sector rotation and political pressure. Explore three trading ideas to benefit from falling prices.
To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.
Hologic Inc NASDAQ/NGS:HOLXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for HOLX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding HOLX are favorable with net inflows of $115.08 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Hologic, Inc. announced today that the Company plans to release its financial results for the second quarter of fiscal 2019 on Wednesday, May 1, 2019, after the market closes.
ResMed (RMD) continues to invest and expand presence in high-growth markets like China, South Korea, India, Brazil and many countries in Eastern Europe.
Proposed rule highlights the risks of breast density and emphasizes important advances in mammography technology, including 3D mammography
The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.
Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.
With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.
Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.
National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.
A study by TeleFlex (TFX) sheds light on the real-world retrospective data on 30 men suffering urinary retention treated with the UroLift System.
Hologic, Inc. (HOLX), an innovative medical technology company focused on improving women’s health and well-being through early detection and treatment, today opened its first Learning and Experience Centre in Zaventem, Belgium (a municipality neighboring Brussels). The state-of-the-art facility provides comprehensive training for customers, healthcare professionals and employees across Hologic’s Europe, Middle East and Africa (EMEA) region, centralizing the education experience for Hologic’s technologies.
Phibro Animal (PAHC) has been gaining from strong volume growth in foreign markets. However, adverse currency movements remain a concern.
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.
The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.
Align Technology (ALGN) will be integrating Digital Smile Design's methodology in functional and aesthetic dentistry with its end-to-end digital workflow covering iTero scanners and Invisalign system.